Contraceptive Hormones, Immunity, and Microbiome Evaluation (CHIME)

A Prospective Cohort Study Evaluating the Impact of Three Progestin-based Hormonal Contraceptive (HC) Methods on Immunologic Changes in the Female Genital Tract (FGT) and Systemically

The study is a prospective cohort study to explore the mechanisms underlying the HIV risk associated with pharmacologic doses of exogenous sex hormones via hormonal contraceptives specially progestin-containing hormonal contraception (HC). The study seeks to test that HC induce immunologic changes capable of altering HIV susceptibilities, that these effects will vary by contraceptive type, and that they will be modified by the vaginal microenvironment.

Study Overview

• Status: Recruiting
• Conditions: Hormonal Contraception
• Intervention / Treatment: Drug: Depot medroxyprogesterone acetate (DMPA); Drug: Etonogestrel implant (Eng-Implant); Drug: Levonorgestrel IUD (Lng-IUD)

Detailed Description

This study is a translational research project to explore the mechanisms underlying the HIV risk associated with pharmacologic doses of exogenous sex hormones (via hormonal contraceptives). Emerging data suggests that certain hormonal contraceptives may induce mucosal and systemic immune changes that could increase the risk of infection with HIV. While several studies have aimed to characterize immunologic changes in women using hormonal contraceptives, the nature and the magnitude of these immune changes have not been adequately defined due to limitations in study design rigor, and small and statistically underpowered sample sizes.

The study will prospectively recruit cohorts of HIV-uninfected women initiating hormonal contraception to characterize systemic and lower genital tract innate and adaptive immunologic changes that occur over a course of up to 4 months. This study will test the overarching hypothesis that hormonal contraceptives induce systemic and mucosal immune changes capable of altering susceptibilities and/or responses to diseases including HIV infection, and that these effects vary markedly in nature and magnitude by contraceptive type and will be modified by the vaginal microenvironment. The main aim is to determine the immunologic alterations in female genital and systemic immune profile associated with depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant) and Levonorgestrel IUD (Lng-IUD).

• Study Type: Observational
• Enrollment (Estimated): 225

Contacts and Locations

• Study Contact: Name: Alicia Smith, PhD; Phone Number: 404-712-5006; Email: alicia.smith@emory.edu

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30303
      • Recruiting
      • Grady Health System
      • Contact: Alicia Smith, PhD; Phone Number: 404-712-5006; Email: alicia.smith@emory.edu
      • Principal Investigator: Alicia Smith, PhD
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • The Emory Clinic, Bldg A., 2nd Floor, 1365 Clifton Road, NE
      • Contact: Alicia Smith, PhD; Phone Number: 404-712-5006; Email: alicia.smith@emory.edu
      • Principal Investigator: Alicia Smith, PhD
    • Atlanta, Georgia, United States, 30342
      • Recruiting
      • Atlanta Women's Center
      • Contact: Alicia Smith, PhD; Phone Number: 404-712-5006; Email: alicia.smith@emory.edu
      • Principal Investigator: Alicia Smith, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 45 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Participants will be selected from several sites in the greater Atlanta community to include: family planning clinics, OB/GYN practice/reproductive heath clinics, community based recruitment through postings at community centers, community health fairs, coffee shops and local universities, as well as web-based recruitment through the national ResearchMatch.

Description

Inclusion Criteria:

• Female sex, defined by sex at birth.
• Age ≤ 45 years. If < 18 years of age, participant must be capable of providing assent, understanding and complying with all study procedures, and have written informed consent from a parent or legal guardian.
• Normal menses (occurring within 22-35 day intervals) for > 2 cycles. Women who are postpartum or post-abortion who have resumed menses are eligible.
• Intact uterus and cervix.
• Interested in initiating HC and willing to accept DMPA, Eng-Implant or Lng-IUD.
• Willing to delay initiation of HC for up to 1 month.
• Able and willing to provide informed consent, and undergo study procedures.
• Negative HIV test by Ora-Quick© method at Screening Visit.
• Agree to abstain from vaginal intercourse or using intra-vaginal products for 1 day prior to each study visit.

Exclusion Criteria:

• Pregnant or planning to become pregnant within the next year.
• Breastfeeding, if not having active menstrual cycles. Breastfeeding is not exclusionary if the participant is actively cycling.
• History of loop electrosurgical excision procedure (LEEP), conization, or cryosurgery within the past year.
• Current use of systemic HC or IUD, based on self-report and/or hormonal testing.
• Taking concurrent medications that interact with selected HC.
• Contraindications to selected contraceptive per the Center for Disease Control medical eligibility criteria or judgment of clinician.
• Allergy to lidocaine for cervical biopsies (if consenting to optional biopsies).

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Depot medroxyprogesterone acetate (DMPA); This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.	Drug: Depot medroxyprogesterone acetate (DMPA); Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks; Other Names: Depo-Provera; Medroxyprogesterone acetate (MPA)
Etonogestrel implant (Eng-Implant); This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.	Drug: Etonogestrel implant (Eng-Implant); A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.; Other Names: Nexplanon
Levonorgestrel IUD (Lng-IUD); This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.	Drug: Levonorgestrel IUD (Lng-IUD); The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.; Other Names: Mirena; Copper

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in mean total leukocytes and CD4+ T-cells expressing CCR5 in the lower female genital tract (FGT) among the three intervention groups pre and post contraception	Using Fortessa flow cytometer and Luminex, effector memory Cluster Differentiation 4 (CD4) + Thymocytes (T) cells will be analyzed for surface expression of HIV coreceptors cell surface receptor C-C chemokine receptor type 5 (CCR5) and reported as percent of total leukocytes and CD4+ T-cells. The cytometry will use the cervicovaginal fluid (CVF) collected by cervicovaginal lavage (CVL).This test will characterize the alterations in female genital and systemic immune profiles associated with three long-acting progestin-only Hormonal Contraception.	Week 1 and Week 3 (pre contraception), and 13 and 15 weeks after initiating contraception
Change in Nugent's score among the three intervention groups pre and post contraception	The Nugent Score is a Gram stain scoring system for vaginal swabs to diagnose bacterial vaginosis. The Nugent score is calculated by assessing for the presence of large Gram-positive rods (Lactobacillus morphotypes; decrease in Lactobacillus scored as 0 to 4), small Gram-variable rods (Gardnerella vaginalis morphotypes; scored as 0 to 4), and curved Gram-variable rods (Mobiluncus spp. morphotypes; scored as 0 to 2). A score of 7 to 10 is consistent with bacterial vaginosis without culture.	Week 1 and Week 3 (pre contraception), and 13 and 15 weeks after initiating contraception
Percent of expression of 16S rRNA gene sequencing among the three intervention groups pre and post contraception	16 Svedberg ribosomal RNA (16S rRNA) is the component of the 30 Svedberg ribosomal RNA (30S rRNA) small subunit of a prokaryotic ribosome that binds to the Shine-Dalgarno sequence. The genes coding for it are referred to as 16S rRNA gene and are used in reconstructing phylogenies. 16S rRNA gene sequence analysis can better identify poorly described, rarely isolated, or phenotypically aberrant strains, can be routinely used for identification of mycobacteria, and can lead to the recognition of novel pathogens and uncultured bacteria.The term 16S refers to how it settles to when centrifuged (it's called a sedimentation rate, and it's measured in Svedberg (S) units).	Week 1 and Week 3 (pre contraception), and 13 and 15 weeks after initiating contraception

Collaborators and Investigators

• Sponsor: Emory University
• Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institutes of Health (NIH)
• Investigators: Principal Investigator: Alicia Smith, PhD, Emory University

Study record dates

Study Major Dates

• Study Start (Actual): December 7, 2018
• Primary Completion (Estimated): September 1, 2024
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: September 4, 2018
• First Submitted That Met QC Criteria: September 4, 2018
• First Posted (Actual): September 6, 2018

Study Record Updates

• Last Update Posted (Actual): September 13, 2023
• Last Update Submitted That Met QC Criteria: September 8, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Human immunodeficiency virus; Sexually Transmitted Diseases; Contraceptives
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Contraceptives, Oral; Contraceptive Agents, Female; Contraceptives, Oral, Synthetic; Contraceptives, Oral, Hormonal; Contraceptive Agents, Male; Levonorgestrel; Medroxyprogesterone Acetate; Medroxyprogesterone; Etonogestrel
• Other Study ID Numbers: IRB00104017; R01HD095741-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No